Ask the Expert

Burden of Multiple Myeloma

Treatment resources

Clinical trials

Download the ClinTrial Refer App

Latest News

Article of the week: Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

Myeloma Australia’s Medical and Scientific Advisory Group (MSAG)┬ápresents the article of the week. Lenalidomide, bortezomib, and dexamethasone (RVd) followed by...
Continue Reading

Multiple Myeloma Research Review

Highlights include: Associations with OS in NZ MM patients VTE risk with lenalidomide regimens for MM despite thromboprophylaxis Retrospective study...
Continue Reading

Australian clinicians report on real world use of bortezomib in elderly MM patients

Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who...
Continue Reading

Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma

The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple...
Continue Reading

Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment

A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might...
Continue Reading


Every quarter we’ll post news and information in our myeloma newsletter. If you would like to join the community of patients and caregivers receiving this subscribe below.